No evidence of disease activity after fingolimod treatment: A three-year real-world comparison of pre- and post-treatment outcomes in multiple sclerosis

Key Points

• No evidence of disease activity is observed after three years of fingolimod treatment.
• The study compares outcomes before and after treatment in a real-world setting over three years.
• Analysis includes assessments of disease activity metrics among multiple sclerosis patients.
• These findings highlight the potential effectiveness of fingolimod in managing multiple sclerosis.